Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells

• Published in: International journal of molecular sciences 2022-10, Vol.23 (20), p.12517
• Main Authors: Ren, Bingtao, Zhou, Jieyun, Hu, Yingyi, Zhong, Ruihua, Lv, Qiaoying, Xie, Shuwu, Li, Guoting, Yang, Bingyi, Chen, Xiaojun, Zhu, Yan
• Format: Article
• Language: English
• Subjects: AKT protein; Cancer therapies; Cell proliferation; Endometrial cancer; Endometrium; Hyperplasia; Hypothyroidism; Initiation factor eIF-4G; Kinases; medroxyprogesterone acetate; mTOR signaling pathway; nomegestrol acetate; Patients; Progesterone; Progestin; progestin resistance; Proteins; Rapamycin; Response rates; Serum levels; Signal transduction; Thyroid gland; thyroid hormone receptor; Thyroid hormones; TOR protein; Transcriptomics; Triiodothyronine; Western blotting
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232012517

Progestin resistance is a major obstacle to conservative therapy in patients with endometrial cancer (EC) and endometrial atypical hyperplasia (EAH). However, the related inducing factor is yet unclear. In this study, thyroid hormone and its receptor α (TRα) and β (TRβ) of patients were assayed. THRB-silenced RL95-2 and KLE EC cells were cultured to investigate the response of progestins. Transcriptomics and Western blotting were performed to investigate the changes in signaling pathways. We found that THRB, rather than THRA, knockdown promoted the viability and motilities of RL95-2 cells but not KLE cells. The suppressive effect of progestins on cell growth and motility significantly decreased in THRB-silenced RL95-2 cells. Multiple proliferation-related signaling pathways were enriched, and the activities of mammalian targets of rapamycin (mTOR)/4e-binding protein 1 (4EBP1)/eukaryotic translation initiation factor 4G (eIF4G) rather than phosphorylated protein kinase B (Akt) were remarkably boosted. Progestin treatment enhanced the effects, and the augmentation was partially abated on supplementation with T3. In THRB-knockdown KLE cells, the progestins-activated partial signaling pathway expression (either mTOR or eIF4G), and supplementation with T3 did not induce noticeable alterations. The serum levels of triiodothyronine (T3) were significantly lower in patients with EC compared with healthy women. A strong expression of TRβ was observed in most patients with EC and EAH sensitive to progestin treatment. In contrast, TRα positive expression was detected in less than half of the patients sensitive to progestin therapy. In conclusion, THRB knockdown enhanced the viability and motility of type I EC cells and attenuated the suppressive effects of progestins by activating the mTOR-4EBP1/eIF4G pathway. Lower expression of THRB is likely correlated with progesterone resistance.